Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeant Pharmaceuticals International Inc.

www.valeant.com

Latest From Valeant Pharmaceuticals International Inc.

Stock Scan November 2017: Generics get volatile

Generic drug producers endured very mixed fortunes on the world's stock markets, with firms ending November at opposite ends of Scrip's Stock Scan monthly league table.

Growth Sales & Earnings

Novartis Champions Cosentyx With More Long-Term Psoriasis Data

Although its focus may be shifting somewhat towards other indications, the Swiss major has reported study read-outs that demonstrate the long-term efficacy of its IL-17A inhibitor blockbuster in nail and palmoplantar psoriasis.

Immune Disorders Dermatology

Finance Watch: A Bountiful November Harvest For Venture-Backed Biopharma

Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.

Financing Business Strategies

Deal Watch: Genentech Expands Upon Arvinas PROTAC Collaboration

The Roche affiliate doubles the potential monetary value of partnership focused on PROTAC technology in a range of therapeutic areas. Cardinal sells off Chinese business for $1.2bn, while Novartis licenses Homology’s gene-editing technology.

Deals Business Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register